Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib. [More]

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial. [More]
Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Frail elderly people living in residential care facilities are at increased risk of severe illness or death from outbreaks of viral gastroenteritis. [More]
L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Healthy children attending day-care centres have a significantly lower risk of getting diarrhoea or respiratory tract infections when given a daily supplement of Lactobacillus reuteri Protectis, a study in 336 children shows. "Our study confirms earlier published data in proving that preventive use of L. reuteri Protectis in healthy children reduces diarrhoeic episodes. [More]

Study shows SuperMum campaign improves handwashing behaviour

An analysis of a unique “SuperMum” handwashing campaign shows for the first time that using emotional motivators, such as feelings of disgust and nurture, rather than health messages, can result in significant, long-lasting improvements in people’s handwashing behaviour, and could in turn help to reduce the risk of infectious diseases. [More]

Altering sunitinib dosing schedule improves tolerability

Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. [More]

Avastin can prolong the lives of women with advanced cervical cancer

New data showing cancer treatment Avastin (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine. [More]
Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show. [More]

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend. [More]
Scientists to decode intestinal disease bacteria using genome sequencing technologies

Scientists to decode intestinal disease bacteria using genome sequencing technologies

​The University of Liverpool is to decipher the genomes of the UK's main bacterial cause of food poisoning which results in over 21,000 hospital admissions and 100 deaths each year. [More]
European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age. [More]
Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis. [More]
GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations. [More]
IQWiG study finds no added benefit of teriflunomide

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). [More]

Scientists use new method to map response of every salmonella gene to conditions in human body

Scientists have used a new method to map the response of every salmonella gene to conditions in the human body, providing new insight into how the bacteria triggers infection. [More]

New research reveals novel way to develop anti-diarrhoeal drugs

New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs. [More]

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

Restricting the use of antibiotics is unlikely to stop the spread of drug resistance in typhoid fever, according to a study funded by the Wellcome Trust and published in the journal eLife. [More]

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly). [More]

UNICEF, WHO support breastfeeding to avoid illness and deaths of children in Philippines

UNICEF and WHO today called on those involved in the response to the Philippines' Typhoon Haiyan (Yolanda) disaster to promote and protect breastfeeding to avoid unnecessary illness and deaths of children. [More]

Bangladesh outperforms Asian neighbours despite low spending on health care

Exceptional improvements in the survival of infants and children under 5 years of age, life expectancy, immunisation coverage, and tuberculosis control in Bangladesh are part of a remarkable success story for health in the South Asian country, according to a major new Series published in The Lancet. This is despite low spending on health care, a weak health system, and widespread poverty. [More]